QIAGEN Announces High Accuracy of Bioinformatics Solutions in Women's Health Genetic Screening

ORLANDO, GERMANTOWN, Maryland, and HILDEN, Germany, October 19, 2017 /PRNewswire/ --

QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) today announced the results of a study evaluating the accuracy of the QIAGEN Clinical Insight (QCI) solution by Counsyl, a genetic screening and genetic counseling company. In an evaluation, Counsyl - an early QCI adopter - found that it reduced the time required to search for literature references to interpret and score variants by 75 percent while maintaining accuracy. As a result, Counsyl has implemented QCI as an integral part of its literature search process to increase productivity and scalability. Results of the evaluation are presented today in a poster at the American Society of Human Genetics (ASHG).

Click here [https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-19-Counsyl-ASHG?sc_lang=en ] for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-19-Counsyl-ASHG?sc_lang=en



        Investor Relations 
        John Gilardi 
        E-Mail: ir@QIAGEN.com 

        Public Relations 
        Dr. Thomas Theuringer 
        E-Mail: pr@QIAGEN.com